Robby asks Alan about what he’s most looking forward to at ECTRIMS 2016.
Robby: What are you most looking forward to here?
Professor Alan Thompson, Neurologist: Well, I think this, ECTRIMS is just an extraordinary event. It gets bigger every year, it’s the MS meeting. So it will be the meeting where the most interesting results are announced. So what I like about it is I like going to the main lectures where you get a real summary of where things are, so the early lectures each day, and I also like to listen to the results of trials. So we know there are going to be some interesting trials presented and my main interest is in progressive MS, so I’m looking for results in progression, which are very few, but we know there’s going to be a trial discussed on Saturday, which I think is going to suggest that there are positive results in a trial for secondary progressive MS, which would be amazing. I mean last year in Barcelona we had the results of a positive trial for primary progressive MS, Ocrelizumab, and that’s now going through the process to be licensed. So if this is a second drug for progression, that would be just fantastic.
Robby: There’s actually nothing apart from relapse remitting drugs?
Professor Alan Thompson: At the moment we have none. We have how many? 12, 13, 14 drugs for relapsing remitting MS, we’ve nothing for progressive MS. So this is really a great breakthrough and if I plug the Progressive MS Alliance, which I am very involved in, that’s all about raising the profile of progression and encouraging more early trials in progressive MS and then definitive trials. But this would be basically two definitively positive trials in progression, which would be fantastic.
Join the Shift.ms community: https://shift.ms/
Watch more videos here: